On November 5th, the TBSI-CSI (National University of Singapore Cancer Institute) Cancer Accuracy Methodology Seminar was held at Nanshan Zhiyuan. The event brought together leading scientists from China, Australia, Singapore, and India to exchange research on precision therapy assessment, molecular inhibitors, liver protein recoding, chromosomal labeling and nucleic acid detection, and transcriptional activators. Research and future exploration.

At present, the main treatment methods for cancer are surgical treatment, chemical medicine treatment, radiation therapy, treatment of traditional Chinese medicine, targeted therapy, immunotherapy and some local treatment. Surgical treatment has long been the most important method of curing cancer. However, with the gradual improvement of medical level in recent years, precise treatment methods represented by targeted therapy have also been used more.

In 2015, the Obama administration announced the launch of the Precision Medicine Initiative, which will push precision treatment to the national development strategy. In fact, the era of precision treatment is coming. For cancer treatment drugs, China also included 17 anti-cancer drugs in the medical insurance reimbursement list in early October this year, including a variety of tumor-targeted drugs.

The so-called targeted therapy refers to the design of corresponding therapeutic drugs at the cellular molecular level for the already identified carcinogenic sites. After the drug developed by this method enters the body, it will select a carcinogenic site to combine and act, without jeopardizing the normal tissue cells around the tumor, which is more accurate and effective than radiotherapy. According to public data, the first macromolecular targeting drug, rituximab, for non-Hodgkin's lymphoma was launched in 1997, and the first small molecule BCR-ABL inhibitor, imatinib, was introduced in 2001. The market, which marks the gradual entry of cancer treatment into the age of targeting.

Professor Peter Lobie, director of the Center for Precision Medicine and Public Health at TBSI (Tsinghua-Berkeley Shenzhen College), pointed out that Shenzhen's layout in the field of precision treatment has deepened in recent years. In 2015, the Sixth Session of the Shenzhen Municipal People's Congress has promoted the construction of “Healthy Shenzhen” into the government work report, and promoted the support of relevant departments to promote the implementation of precision medical plans, including the application of targeted drug development.

In this symposium, Dr. Maohua Ma, the chief researcher of TBSI, shared his “Microfluidics based 3D microtumours for micro-precision therapy” from his field of scientific and engineering interface research. The evaluation of precision therapies; and Sudhakar JHA, Principal Investigator, National Institute of Cancer Research, National University of Singapore, shared "How and why TIP60.com is hacked by viruses?" His research team helps to achieve precise treatment of cancer by understanding the regulation of chromatin remodeling complexes and their role in cancer prevention and intervention.

"We found that approximately 6,000 low-repetition regions are enriched with multiple off-targets, which improves the efficiency of the CRISPR marker at these 6000 chromosomal sites. (We found around 6000 low-repetitive regions enriched with multiple off-targets, which enhances the efficiency of CRISPR labeling for these 6000 chromosome loci.)" Dr. Peiwu Qin, Principal Investigator of TBSI, said in a keynote speech, "These results demonstrate the feasibility of our method to monitor the location and dynamics of repetitive and non-repetitive genomic regions in living cells. These results demonstrate the feasibility of our approach to monitor the position and dynamics of both repetitive and non-repetitive genomic regions in live cells.) In the future, this technology may contribute to the related research and development of targeted drugs.

Citing the data from the recent China Cancer Research Association's "China Malignant Oncology Development Report (2017)", in 2016, China's urban malignant tumors ranked first in the death of the entire population. At present, the incidence and mortality rate of lung cancer in China account for 35.78% and 37.56% of the world respectively, which is the country with the most lung cancer incidence and death in the world. In addition, nearly 50% of all cases of gastric cancer incidence and death in the world occur in China. Promoting the clinical application of relevant scientific research results can effectively reduce the incidence and mortality of cancer.

It is reported that TBSI is an academic research institution jointly established by Tsinghua University and Berkeley University of California with the support of the Shenzhen Municipal Government in September 2014. It is committed to the concept of “disciplinary crossover”, “internationalization” and “industry partnership”. Explore the training model of “college-government-enterprise” tripartite cooperation.

There are three research centers under the TBSI, namely the Environmental Science and New Energy Technology Research Center, the Data Science and Information Technology Research Center, and the Precision Medicine and Public Health Research Center. Among them, as the organizer of the seminar, the Center for Precision Medicine and Public Health, in addition to cancer treatment research, also integrated molecular diagnostic systems, stem cell therapy and regenerative medicine, biomedical detection and imaging, macromolecular platform translation medicine and Research and exploration in areas such as biomanufacturing.

ANTIMICROBIAL SERIES

Puyang Linshi Medical Supplies Co., Ltd. , https://www.linshihealths.com